Filing step-change
GANGAPHARM · 2026-10
Quarterly observations that moved versus the prior period in 2026-10. Facts only — not a call to act.
Narrative date 2026-10-21 · Evidence medium
Gangapharm's quarterly performance has shown significant improvement in its gross margin, accelerating to 53.65%, up from 2.15%.
Raw Evidence
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 53.65 % | 2.15 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 2.15 % | 3.59 | ▼ |
| REVENUE_GROWTH_YOY | 10.2 % | 104.8 | ▼ |
Cite this
Source: Samhati filing step-change for GANGAPHARM (2026-10). Observation: Gangapharm's quarterly performance has shown significant improvement in its gross margin, accelerating to 53.65%, up from 2.15%. Evidence quality: medium. Not investment advice — no buy, sell, or hold recommendation. Full narrative (Pro): https://samhati.ai/pricing Page: https://samhati.ai/stock/gangapharm/q/2026-10
Other periods